Institutional
Omega Fund Management, LLC
CIK 0001637359
$163.1M
Reported AUM
10
Positions
Q1 2026
Period
2026-05-15
Filed
The Brief · Omega Fund Management, LLC · Q1 2026
AI · grounded in 13F
Omega Fund Management, LLC closed its entire position in Upstream Bio Inc. UPB, reducing its exposure by $36.0M. The fund also trimmed its holdings in Alumis Inc. ALMS by 63.1% and Kestra Med Technologies Ltd KMTS by 25.6%. Conversely, the manager accumulated more shares of Bicara Therapeutics Inc. BCAX, increasing the position by 8.5%.
Portfolio · Q1 2026
Top holdings
| # | Stock | Issuer | Price | Day % | 1Y Gr. | 5Y Gr. | Value | % of book | Δ shares (QoQ) | Status |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BCAX | Bicara Therapeutics Inc. | $26.90 | 2.40% | 149.48% | 10.94% | $47.6M | 29.16% | — | HELD |
| 2 | NUVB | Nuvation Bio Inc. | $6.30 | -5.90% | 200.45% | -27.41% | $34.7M | 21.25% | — | HELD |
| 3 | BBOT | BridgeBio Oncology Therapeutics Inc. | $8.15 | -4.12% | -21.89% | -21.63% | $29.4M | 18.05% | — | HELD |
| 4 | KMTS | Kestra Med Technologies Ltd | $22.71 | -1.90% | 50.52% | -3.78% | $20.4M | 12.49% | — | HELD |
| 5 | BBNX | Beta Bionics Inc. | $13.35 | -6.45% | -12.99% | -31.95% | $13.2M | 8.08% | — | HELD |
| 6 | — | enGene Holdings Inc. | — | — | — | — | $6.0M | 3.66% | — | HELD |
| 7 | ALMS | Alumis Inc. | $28.12 | -2.87% | 580.87% | 128.62% | $5.3M | 3.26% | — | HELD |
| 8 | SANA | Sana Biotechnology, Inc. | $3.13 | -3.66% | -19.57% | -86.89% | $2.4M | 1.49% | — | HELD |
| 9 | IMA | ImageneBio, Inc. | $5.58 | -5.58% | -67.71% | -96.39% | $2.3M | 1.40% | — | HELD |
| 10 | REPL | Replimune Group | $10.54 | 94.82% | -28.82% | -82.97% | $1.9M | 1.17% | — | HELD |
Source: SEC EDGAR · accession 0001193125-26-225480. 13F discloses long positions only — shorts, foreign equities, and options are excluded.